Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001837197 | SCV002097684 | uncertain significance | COACH syndrome 1; Meckel syndrome, type 6; Joubert syndrome 9 | 2020-06-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001885379 | SCV002251217 | uncertain significance | Familial aplasia of the vermis; Meckel-Gruber syndrome | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with lysine at codon 226 of the CC2D2A protein (p.Glu226Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with CC2D2A-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CC2D2A protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |